ALPS Advisors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

ALPS Advisors’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-31,316	Closed	-$3.36M	–	1047
2023 Q1	$3.36M	Buy	31,316 +2,814	+10%	+$324K	0.03%	216
2022 Q4	$3.14M	Buy	28,502 +6,205	+28%	+$402K	0.03%	227
2022 Q3	$1.32M	Sell	22,297 -954	-4%	-$43.7K	0.01%	385
2022 Q2	$656K	Sell	23,251 -16,904	-42%	-$490K	0.01%	538
2022 Q1	$1.52M	Sell	40,155 -4,909	-11%	-$194K	0.02%	272
2021 Q4	$1.78M	Buy	+45,064	New	+$1.41M	0.02%	301

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

ALPS Advisors's RXDX Position: Q2 2023 in Review

ALPS Advisors sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 31,316 shares — an estimated $3.36M sold.

ALPS Advisors first reported a position in RXDX in Q4 2021 and held it in 6 quarters. The position peaked at $3.36M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

ALPS Advisors reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
ALPS Advisors sold 31,316 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $3.36M.
ALPS Advisors first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
ALPS Advisors's Prometheus Biosciences, Inc. Common Stock position peaked at $3.36M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on ALPS Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.